QIAGEN N.V.: QIAGEN Announces 20-F Annual Report Filing for 2020 Results
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that it has filed its annual report, including its audited consolidated financial statements on Form 20-F, for the year ended December 31, 2020, with the U.S. Securities and Exchange Commission. The document can be accessed on QIAGEN s website at https://corporate.qiagen.com/investor-relations/financial-reports
About QIAGEN
QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. Our sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. Automation soluti
QIAGEN N V : QIAGEN Launches QIAsphere Cloud-Based Connectivity Solution to Enhance QIAstat-Dx Capabilities in Digital Diagnostics
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
QIAGEN N V : QIAGEN Launches QIAcube Connect MDx Platform for Automated Sample Processing in Diagnostic Labs
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
QIAGEN and INOVIO Pharmaceuticals: QIAGEN and INOVIO Expand Collaboration to Develop Next Generation Sequencing (NGS) Companion Diagnostic for INOVIO s VGX-3100 for Advanced Cervical Dysplasia
QIAGEN s bioinformatic expertise raises predictive biomarker power in INOVIO s patient selection
First-in-class next generation sequencing (NGS) assay designed for use on Illumina NextSeq 550Dx
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) and INOVIO Pharmaceuticals (NASDAQ: INO) today announced an extension of their partnership with a new master collaboration agreement to develop liquid biopsy-based companion diagnostic products based on next-generation sequencing (NGS) technology to complement INOVIO s therapies
.
( Complementary when referring to the US regulatory pathway.)
The initial project in this expanded collaboration focuses on the co-development of a diagnostic test that identifies women who are most likely to benefit from clinical use of VGX-3100, INOVIO s immunotherapy
QIAGEN : Expands Supervisory Board With Appointment of a New Member
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.